Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04260802
Title A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Ocellaris Pharma, Inc.
Indications

sarcoma

ovarian cancer

Merkel cell carcinoma

transitional cell carcinoma

skin squamous cell carcinoma

urinary bladder cancer

triple-receptor negative breast cancer

head and neck squamous cell carcinoma

cervical cancer

hepatocellular carcinoma

Advanced Solid Tumor

stomach cancer

renal cell carcinoma

lung non-small cell carcinoma

Therapies

OC-001 + unspecified PD-L1 antibody

OC-001 + unspecified PD-1 antibody

OC-001

Age Groups: senior | adult
Covered Countries CAN

Additional content available in CKB BOOST